arrow
J

Jarosław B. Ćwikła

University of Warmia and Mazury
H指数:35
被引数:7,578

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial

[177Lu]Lu-edotreotide与依维莫司治疗胃肠胰神经内分泌肿瘤的比较(COMPETE研究):一项III期、多中心、随机、开放标签、优效性试验

2026-07-020
PRE
The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [177Lu]Lu-DOTA-TATE: A post-authorisation safety study

LysaKare输注对接受[177Lu]Lu-DOTA-TATE治疗的可治疗性胃肠胰神经内分泌肿瘤患者血清钾水平的影响:一项上市后安全性研究

2026-04-130
OA
Biochemical and radiological efficacy of systmic lanreotide therapy of patients with advanced, unresectable, nonmetastatic paraganglioma/pheochromocytoma (PPGL) sporadic and hereditary

晚期、不可切除、无转移的副神经节瘤/嗜铬细胞瘤(PPGL,散发性和遗传性)患者系统性兰瑞肽治疗的生化及放射学疗效

2024-09-010
PRE
Overall survival (OS) and progression-free survival (PFS) in patients with advanced, non-resectable, progressive rectal NET treated with 90Y DOTA-TATE, 177Lu DOTA-TATE and mix of both as systemic radioligand therapy: Real-world data

总生存期(OS)和无进展生存期(PFS)在晚期、不可切除、进展期直肠神经内分泌肿瘤患者中,接受90Y DOTA-TATE、177Lu DOTA-TATE及两者联合作为系统性放射性配体治疗的真实世界数据

2024-09-010
PRE
Outcomes of cardiac surgical treatment for carcinoid heart disease
2022-02-283
OA